Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform:
Third Quarter 2026 Financial Results
- Third quarter 2026 Revenue of
$28 million compared to$29 million in the comparable prior year period, a decrease of 6%. Revenue increased from$20 million in the second quarter of 2026. - Third quarter 2026 GAAP net loss from continuing operations of
($41) million , compared to($73) million in the comparable prior year period. - Third quarter 2026 Adjusted EBITDA of
($22) million , improved from($53) million in the comparable prior year period. - Cash, cash equivalents and marketable securities balance as of
September 30, 2026 of$285 million . - Third quarter 2026 cash burn of
$27 million .
"Ginkgo now has two core offerings built on one autonomous lab platform," said
Recent Business Highlights & Strategic Positioning
- Two prevailing offerings built on one autonomous lab platform.
- Autonomous Labs Equipment: we sell RAC + Catalyst systems to pharma, national labs, universities and the
U.S . government, including Novo,Pacific Northwest National Laboratory , the NSF and ARPA-H. - Cloud Lab Services: we run experiments in Nebula, the world’s largest autonomous lab with more than 100 reconfigurable automation carts (RACs), delivering onshore ADME, DRUG-seq and antibody data for pharma, and AI training data for frontier labs and techbio companies.
- The
U.S . government is making autonomous labs national infrastructure through theGenesis Mission , the NSF’s~$400 million Programmable Cloud Laboratories (PCL) Test Bed, and the$1.5 billion X-Labs initiative, where Ginkgo is providing access to Nebula, as announced by theWhite House Office of Science and Technology Policy onOctober 8 .
- Autonomous Labs Equipment: we sell RAC + Catalyst systems to pharma, national labs, universities and the
Autonomous Labs are growing with new deals.- Novo: an autonomous lab sale to a top-tier pharma company at Novo’s new
Waltham, Massachusetts R&D site. - ARPA-H GIVE: subcontract worth up to
$17.5 million to put RACs and Catalyst into RNA-medicine manufacturing for the first time. - Building on momentum from previously-announced
Caltech ,University of Maryland andNorthwestern commissions of Ginkgo-built labs under the NSF’s PCL Test Bed, and MIT Media Lab’s construction of a RAC-based cloud lab.
- Novo: an autonomous lab sale to a top-tier pharma company at Novo’s new
Cloud Lab is growing with new pharma logos and AI data generation.- Our ADME-One service is orders of magnitude cheaper than
WuXi , with work done inBoston ; 22 ADME customers signed in Q3 and 20 were first-time Ginkgo customers. - Takeda, Argenx, Lundbeck and AbbVie founded our
Antibody Developability Consortium ; GSK, Novartis and Biogen also signed new work. - Frontier AI labs like OpenAI are using our
Cloud Lab for AI data generation.
- Our ADME-One service is orders of magnitude cheaper than
Full Year 2026 Outlook
- Ginkgo reaffirms expected total cash burn of (
$150 )-($125) million in 2026.
Conference Call Details
Ginkgo will host a videoconference today,
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/
Audio-Only Dial Ins:
+1 646 876 9923 (
+1 301 715 8592 (
+1 305 224 1968 (
+1 689 278 1000 (
+1 312 626 6799 (
+1 507 473 4847 (
+1 346 248 7799 (
+1 719 359 4580 (
+1 408 638 0968 (
Webinar ID: 952 0773 4867
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About
Forward-Looking Statements of
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers’ needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as Novo and OpenAI), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share data)
| As of |
| As of | ||||
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 84,504 |
|
| $ | 167,202 |
|
Marketable securities |
| 200,857 |
|
|
| 255,418 |
|
Accounts receivable, net |
| 11,485 |
|
|
| 24,026 |
|
Accounts receivable - related parties |
| — |
|
|
| 229 |
|
Prepaid expenses and other current assets (includes |
| 13,995 |
|
|
| 24,963 |
|
Total current assets |
| 310,841 |
|
|
| 471,838 |
|
Restricted cash and marketable securities, non-current |
| 84,237 |
|
|
| 38,138 |
|
Property, plant and equipment, net |
| 152,347 |
|
|
| 167,371 |
|
Operating lease right-of-use assets |
| 341,494 |
|
|
| 360,918 |
|
Investments |
| 8,949 |
|
|
| 15,066 |
|
Equity method investments |
| 5,607 |
|
|
| — |
|
Intangible assets, net |
| 39,731 |
|
|
| 53,482 |
|
Other non-current assets |
| 1,246 |
|
|
| 9,029 |
|
Assets held for sale |
| — |
|
|
| 3,854 |
|
Total assets | $ | 944,452 |
|
| $ | 1,119,696 |
|
Liabilities and Stockholders’ Equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 7,181 |
|
| $ | 10,566 |
|
Deferred revenue (includes |
| 6,388 |
|
|
| 18,946 |
|
Accrued expenses and other current liabilities (includes |
| 52,280 |
|
|
| 66,458 |
|
Total current liabilities |
| 65,849 |
|
|
| 95,970 |
|
Non-current liabilities: |
|
|
| ||||
Deferred revenue, net of current portion (includes |
| 71,977 |
|
|
| 75,182 |
|
Operating lease liabilities, non-current |
| 397,198 |
|
|
| 417,078 |
|
Other non-current liabilities |
| 16,791 |
|
|
| 22,876 |
|
Total liabilities |
| 551,815 |
|
|
| 611,106 |
|
Commitments and contingencies (Note 10) |
|
|
| ||||
Stockholders’ equity: |
|
|
| ||||
Preferred stock, |
| — |
|
|
| — |
|
Common stock, |
| 6 |
|
|
| 6 |
|
Additional paid-in capital |
| 6,713,117 |
|
|
| 6,657,053 |
|
Accumulated deficit |
| (6,320,601 | ) |
|
| (6,150,320 | ) |
Accumulated other comprehensive income |
| 115 |
|
|
| 1,851 |
|
Total stockholders’ equity |
| 392,637 |
|
|
| 508,590 |
|
Total liabilities and stockholders’ equity | $ | 944,452 |
|
| $
| 1,119,696
|
|
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share data)
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Revenue (1) | $ | 27,711 |
|
| $ | 29,380 |
|
| $ | 67,341 |
|
| $ | 106,744 |
|
|
|
|
|
|
|
|
| ||||||||
Costs and operating expenses: |
|
|
|
|
|
|
| ||||||||
Cost of other revenue |
| 1,806 |
|
|
| 4,625 |
|
|
| 6,623 |
|
|
| 14,095 |
|
Research and development |
| 40,945 |
|
|
| 69,353 |
|
|
| 137,075 |
|
|
| 193,646 |
|
General and administrative |
| 28,593 |
|
|
| 36,986 |
|
|
| 97,198 |
|
|
| 111,690 |
|
Restructuring charges |
| — |
|
|
| 721 |
|
|
| — |
|
|
| 8,753 |
|
Total operating expenses |
| 71,344 |
|
|
| 111,685 |
|
|
| 240,896 |
|
|
| 328,184 |
|
Loss from operations |
| (43,633 | ) |
|
| (82,305 | ) |
|
| (173,555 | ) |
|
| (221,440 | ) |
Other income (expense): |
|
|
|
|
|
|
| ||||||||
Interest income, net |
| 3,060 |
|
|
| 5,742 |
|
|
| 9,888 |
|
|
| 17,906 |
|
Loss on equity method investment |
| (2,008 | ) |
|
| — |
|
|
| (6,681 | ) |
|
| — |
|
Gain (loss) on investments |
| (287 | ) |
|
| 3,684 |
|
|
| 486 |
|
|
| (238 | ) |
Other income (expense), net |
| 1,613 |
|
|
| (474 | ) |
|
| (4,725 | ) |
|
| (6,280 | ) |
Total other income (expense) |
| 2,378 |
|
|
| 8,952 |
|
|
| (1,032 | ) |
|
| 11,388 |
|
Loss from continuing operations before income taxes |
| (41,255 | ) |
|
| (73,353 | ) |
|
| (174,587 | ) |
|
| (210,052 | ) |
Income tax (benefit) expense |
| (271 | ) |
|
| 1 |
|
|
| (223 | ) |
|
| (194 | ) |
Net loss from continuing operations | $ | (40,984 | ) |
| $ | (73,354 | ) |
| $ | (174,364 | ) |
| $ | (209,858 | ) |
Net income (loss) from discontinued operations, net of tax |
| — |
|
|
| (7,401 | ) |
|
| 4,083 |
|
|
| (22,154 | ) |
Net loss | $ | (40,984 | ) |
| $ | (80,755 | ) |
| $ | (170,281 | ) |
| $ | (232,012 | ) |
Net income (loss) per share: |
|
|
|
|
|
|
| ||||||||
From continuing operations | $ | (0.64 | ) |
| $ | (1.32 | ) |
| $ | (2.82 | ) |
| $ | (3.82 | ) |
From discontinued operations |
| — |
|
|
| (0.13 | ) |
|
| 0.07 |
|
|
| (0.40 | ) |
Total net loss per share | $ | (0.64 | ) |
| $ | (1.45 | ) |
| $ | (2.75 | ) |
| $ | (4.22 | ) |
|
|
|
|
|
|
|
| ||||||||
Weighted average common shares outstanding: |
| 63,966,054 |
|
|
| 55,633,718 |
|
|
| 61,890,748 |
|
|
| 54,916,539 |
|
Comprehensive loss: |
|
|
|
|
|
|
| ||||||||
Net loss |
| (40,984 | ) |
|
| (80,755 | ) |
|
| (170,281 | ) |
|
| (232,012 | ) |
Other comprehensive (loss) income: |
|
|
|
|
|
|
| ||||||||
Foreign currency translation adjustment |
| (515 | ) |
|
| 27 |
|
|
| (1,128 | ) |
|
| 3,462 |
|
Unrealized (loss) gain on available-for-sale securities |
| (320 | ) |
|
| 316 |
|
|
| (608 | ) |
|
| 340 |
|
Total other comprehensive (loss) income |
| (835 | ) |
|
| 343 |
|
|
| (1,736 | ) |
|
| 3,802 |
|
Comprehensive loss | $ | (41,819 | ) |
| $ | (80,412 | ) |
| $ | (172,017 | ) |
| $ | (228,210 | ) |
(1) Includes related party revenue of zero for the three months ended
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
| Nine Months Ended | ||||||
|
| 2026 |
|
|
| 2025 |
|
Cash flows from operating activities: |
|
|
| ||||
Net loss | $ | (170,281 | ) |
| $ | (232,012 | ) |
Net income (loss) from discontinued operations, net of tax |
| 4,083 |
|
|
| (22,154 | ) |
Net loss from continuing operations |
| (174,364 | ) |
|
| (209,858 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| ||||
Depreciation and amortization |
| 37,152 |
|
|
| 43,695 |
|
Stock-based compensation |
| 31,117 |
|
|
| 51,226 |
|
(Gain) loss on investments |
| (486 | ) |
|
| 275 |
|
Loss on equity method investment |
| 6,681 |
|
|
| — |
|
Change in fair value of notes receivable |
| 6,759 |
|
|
| 5,685 |
|
Change in fair value of contingent consideration |
| — |
|
|
| (4,232 | ) |
Non-cash lease expense |
| 19,423 |
|
|
| 22,449 |
|
Accretion of discount on marketable securities |
| 89 |
|
|
| (2,502 | ) |
Other non-cash activity |
| (1,057 | ) |
|
| 1,611 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Accounts receivable |
| 4,968 |
|
|
| 1,448 |
|
Prepaid expenses and other current assets |
| 3,211 |
|
|
| (775 | ) |
Operating lease right-of-use assets |
| — |
|
|
| 3,814 |
|
Other non-current assets |
| 297 |
|
|
| (38 | ) |
Accounts payable, accrued expenses and other current liabilities |
| (14,312 | ) |
|
| 17,432 |
|
Deferred revenue, current and non-current zero and |
| (14,443 | ) |
|
| (27,448 | ) |
Operating lease liabilities, current and non-current |
| (16,713 | ) |
|
| (18,793 | ) |
Other non-current liabilities |
| (5,276 | ) |
|
| 4,459 |
|
Net cash used in operating activities - continuing operations |
| (116,954 | ) |
|
| (111,552 | ) |
Net cash used in operating activities - discontinued operations |
| (2,353 | ) |
|
| (11,829 | ) |
Net cash used in operating activities |
| (119,307 | ) |
|
| (123,381 | ) |
Cash flows from investing activities: |
|
|
| ||||
Purchases of marketable debt securities |
| (216,800 | ) |
|
| (401,838 | ) |
Maturities of marketable debt securities |
| 231,108 |
|
|
| 73,599 |
|
Purchases of property and equipment |
| (6,552 | ) |
|
| (7,660 | ) |
Proceeds from sale of investment |
| 1,850 |
|
|
| — |
|
Other |
| 512 |
|
|
| 511 |
|
Net cash provided by (used in) investing activities |
| 10,118 |
|
|
| (335,388 | ) |
Cash flows from financing activities: |
|
|
| ||||
Proceeds from ATM offering |
| 23,795 |
|
|
| 10,317 |
|
Payment of issuance costs related to ATM offering |
| (802 | ) |
|
| (355 | ) |
Principal payments on finance leases |
| (19 | ) |
|
| (329 | ) |
Net cash provided by financing activities |
| 22,974 |
|
|
| 9,633 |
|
Effect of foreign exchange rates on cash and cash equivalents |
| (80 | ) |
|
| 353 |
|
Net decrease in cash, cash equivalents and restricted cash |
| (86,295 | ) |
|
| (448,783 | ) |
|
|
|
| ||||
Cash and cash equivalents, beginning of period |
| 167,202 |
|
|
| 561,572 |
|
Restricted cash, beginning of period |
| 45,169 |
|
|
| 44,171 |
|
Cash, cash equivalents and restricted cash, beginning of period |
| 212,371 |
|
|
| 605,743 |
|
|
|
|
| ||||
Cash and cash equivalents, end of period |
| 84,504 |
|
|
| 111,065 |
|
Restricted cash, end of period |
| 41,572 |
|
|
| 45,895 |
|
Cash, cash equivalents and restricted cash, end of period | $ | 126,076 |
|
| $ | 156,960 |
|
The following table presents summary results of the Company’s reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):
| Three Months Ended |
| Nine Months Ended | |||||||||||
|
| 2026 |
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Cell Engineering |
|
|
|
|
|
| ||||||||
Revenue | $ | 27,711 |
| $ | 29,380 |
|
| $ | 67,341 |
|
| $ | 106,744 |
|
Costs and operating expenses: |
|
|
|
|
|
| ||||||||
Cost of other revenue (1) |
| 1,608 |
|
| 2,994 |
|
|
| 5,752 |
|
|
| 9,980 |
|
Research and development (1) |
| 26,670 |
|
| 50,954 |
|
|
| 87,208 |
|
|
| 130,689 |
|
General and administrative (1) |
| 9,317 |
|
| 13,758 |
|
|
| 33,148 |
|
|
| 49,397 |
|
Stock-based compensation (2) |
| 7,767 |
|
| 15,249 |
|
|
| 32,512 |
|
|
| 51,732 |
|
Depreciation and amortization |
| 12,038 |
|
| 13,624 |
|
|
| 37,152 |
|
|
| 43,695 |
|
Restructuring charges (3) |
| — |
|
| 721 |
|
|
| — |
|
|
| 8,753 |
|
Carrying cost of excess space (net of sublease income) (4) |
| 13,989 |
|
| 14,328 |
|
|
| 44,063 |
|
|
| 38,416 |
|
Merger, acquisition and divestiture related expense (income) (5) |
| (45 | ) |
| 57 |
|
|
| 1,061 |
|
|
| (4,478 | ) |
Other (income) expense, net (6) |
| (2,378 | ) |
| (8,952 | ) |
|
| 1,032 |
|
|
| (11,388 | ) |
Loss from continuing operations before income taxes | $ | (41,255 | ) | $ | (73,353 | ) |
| $ | (174,587 | ) |
| $ | (210,052 | ) |
(1) The costs and operating expenses exclude expenses which are separately captioned below.
(2) Includes
(3) See Note 3, Restructuring, for composition of costs.
(4) The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
(5) Represents transaction and integration costs directly related to mergers, acquisitions, and divestitures, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.
(6) Includes interest income, interest expense, gain and loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105540481/en/
INVESTORS:
investors@ginkgobioworks.com
MEDIA:
press@ginkgobioworks.com
Source: